Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

Krista Kinneer,Philipp Wortmann,Zachary A Cooper, Niall J Dickinson,Luke Masterson,Thais Cailleau,Ian Hutchinson,Balakumar Vijayakrishnan,Mary McFarlane,Kathryn Ball,Michael Davies,Arthur Lewis,Yue Huang,Anton I Rosenbaum,Jiaqi Yuan, Jon Chesebrough, Judith Anderton,Noel Monks,Steven Novick,Jixin Wang,Nazzareno Dimasi,R James Christie, Darrin Sabol, Frances Anne Tosto,Yann Wallez,Elisabetta Leo,Mark R Albertella,Anna D Staniszewska,David A Tice,Philip W Howard, Nadia Luheshi,Puja Sapra

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 7|浏览34

暂无评分

摘要

These data provide evidence for the potential utility of AZD8205 for treatment of B7-H4-expressing tumors and support the rationale for an ongoing phase 1 clinical study (NCT05123482). See related commentary by Pommier and Thomas, p. 991.

查看译文

关键词

b7-h4–directed antibody–drug,antibody–drug conjugate,inhibitor,azd8205

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要